A detailed history of Polar Capital Holdings PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Polar Capital Holdings PLC holds 175,000 shares of VRTX stock, worth $87.9 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
175,000
Previous 175,000 -0.0%
Holding current value
$87.9 Million
Previous $73.2 Million 12.13%
% of portfolio
0.5%
Previous 0.46%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $68.6 Million - $82.1 Million
-200,000 Reduced 53.33%
175,000 $71.2 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $24.1 Million - $27.5 Million
85,000 Added 29.31%
375,000 $118 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $80,012 - $90,014
-280 Reduced 0.1%
290,000 $83.7 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $2.74 Million - $3.06 Million
-10,000 Reduced 3.33%
290,280 $84 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $16.5 Million - $19.5 Million
-74,720 Reduced 19.93%
300,280 $78.4 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $13.3 Million - $16.8 Million
75,000 Added 25.0%
375,000 $82.4 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $4.69 Million - $5.53 Million
-25,000 Reduced 7.69%
300,000 $60.5 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $10.4 Million - $12.1 Million
50,000 Added 18.18%
325,000 $69.8 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $56.9 Million - $75.9 Million
275,000 New
275,000 $65 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.